Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Gandhi Shreyans A; Potter Victoria T; Tindell Victoria J; Kesse Adu Rachel; Reiff Zall Laura; Kenyon Michelle; Marsh Judith C W; Ho Aloysius Y; Mufti Ghulam J; Pagliuca Antonio; Lim ZiYi

登录

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

作者：Gandhi Shreyans A; Potter Victoria T; Tindell Victoria J; Kesse Adu Rachel; Reiff Zall Laura; Kenyon Michelle; Marsh Judith C W; Ho Aloysius Y; Mufti Ghulam J; Pagliuca Antonio; Lim ZiYi

来源：52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), 2010-12-04 to 2010-12-07.

出版日期2010-11-19

收藏分享被引浏览

更新时间：2017-04-26 11:20

相似论文
引用论文
参考文献

产品服务

科研之友科研之友机构版科创云

站内浏览

科研成果科研人员科研机构

服务支持

帮助中心隐私政策服务条款

联系方式

在线客服：【立即咨询】客户热线：400-1616-289 电子邮箱：support@scholarmate.com

微信公众号